Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.39 |
| ▸ | GABRP | O00591 | 2/20 | 0.39 |
| ▸ | GABRD | O14764 | 2/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1647022 | 0.89 | HPGD (0.40) | ALDH1A1MEN1TP53HPGDKMT2A | |
| SCHEMBL1647023 | 0.89 | HPGD (0.40) | ALDH1A1MEN1TP53HPGDKMT2A | |
| SCHEMBL1647019 | 0.84 | ALDH1A1 (0.47) | ALDH1A1MEN1TP53HPGDKMT2A | |
| SCHEMBL1646345 | 0.83 | SCN9A (0.45) | — | |
| SCHEMBL1647788 | 0.82 | ALDH1A1 (0.41) | ALDH1A1MEN1TP53HPGDKMT2A | |
| SCHEMBL1645976 | 0.82 | GABRA1 (0.43) | ALDH1A1MEN1TP53HPGDKMT2A | |
| SCHEMBL29316090 | 0.82 | GABRP (0.44) | ALDH1A1MEN1TP53HPGDKMT2A | |
| SCHEMBL2540890 | 0.80 | ALDH1A1 (0.62) | ALDH1A1MEN1TP53HPGDKMT2A | |
| SCHEMBL1646424 | 0.78 | KDM4E (0.41) | ALDH1A1MEN1TP53HPGDKMT2A | |
| SCHEMBL1647063 | 0.78 | MAOA (0.50) | ALDH1A1HPGDSMN1; SMN2TSHRSIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239768-A1 | METHOD FOR PREPARING XANTHINE OXIDASE INHIBITOR | LG CHEM, LTD. (KR) | 2024-07-18 | — | — | US | disclosed |
| US-20240239768-A1 | METHOD FOR PREPARING XANTHINE OXIDASE INHIBITOR | LG CHEM, LTD. (KR) | 2024-07-18 | — | — | US | disclosed |
| US-20240000750-A1 | METHOD FOR PREPARING CRYSTALLINE PARTICLES OF 1-(3-CYANO-1-ISOPROPYL-INDOLE-5-YL)PYRAZOLE-4-CARBOXYLIC ACID, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | LG CHEM, LTD. (KR) | 2024-01-04 | — | — | US | disclosed |
| CN-117203200-A | Process for preparing xanthine oxidase inhibitors | 株式会社LG化学 | 2023-12-08 | — | — | CN | disclosed |
| EP-4218755-A1 | METHOD FOR PREPARING CRYSTALLINE PARTICLES OF 1-(3-CYANO-1-ISOPROPYL-INDOLE-5-YL)PYRAZOLE-4-CARBOXYLIC ACID, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Lg Chem, Ltd. (KR) | 2023-08-02 | — | — | EP | disclosed |
| CN-116456979-A | Process for preparing crystalline particles of 1- (3-cyano-1-isopropyl-indol-5-yl) pyrazole-4-carboxylic acid and pharmaceutical compositions containing the same | 株式会社LG化学 | 2023-07-18 | — | — | CN | disclosed |
| WO-2022231262-A1 | METHOD FOR PREPARING XANTHINE OXIDASE INHIBITOR | 주식회사 엘지화학 | 2022-11-03 | — | — | WO | disclosed |
| WO-2022098057-A1 | METHOD FOR PREPARING CRYSTALLINE PARTICLES OF 1-(3-CYANO-1-ISOPROPYL-INDOLE-5-YL)PYRAZOLE-4-CARBOXYLIC ACID, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 엘지화학 | 2022-05-12 | — | — | WO | disclosed |
| EP-2467378-B1 | COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG LIFE SCIENCES LTD (KR) | 2016-07-27 | — | — | EP | disclosed |
| US-8729273-B2 | Compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same | LG LIFE SCIENCES LTD. (KR) | 2014-05-20 | — | — | US | disclosed |
| US-8729273-B2 | Compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same | LG LIFE SCIENCES LTD. (KR) | 2014-05-20 | — | — | US | disclosed |
| US-8729273-B2 | Compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same | LG LIFE SCIENCES LTD. (KR) | 2014-05-20 | — | — | US | disclosed |
| WO-2012138147-A2 | 1-(3-CYANO-1-ISOPROPYL-INDOL-5-YL)PYRAZOLE-4-CARBOXYLIC ACID CRYSTALLINE FORM AND THE PRODUCING METHOD THEREOF | LG LIFE SCIENCES LTD. (KR) | 2012-10-11 | — | — | WO | disclosed |
| US-20120184582-A1 | NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG CHEM, LTD. (KR) | 2012-07-19 | — | — | US | disclosed |
| US-20120184582-A1 | NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG CHEM, LTD. (KR) | 2012-07-19 | — | — | US | disclosed |
| US-20120184582-A1 | NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG CHEM, LTD. (KR) | 2012-07-19 | — | — | US | disclosed |
| EP-2467378-A2 | NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG Life Sciences Ltd (KR) | 2012-06-27 | — | — | EP | disclosed |
| WO-2011043568-A2 | NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG LIFE SCIENCES LTD. (KR) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240000750-A1 | METHOD FOR PREPARING CRYSTALLINE PARTICLES OF 1-(3-CYANO-1-ISOPROPYL-INDOLE-5-YL)PYRAZOLE-4-CARBOXYLIC ACID, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | IDO1, MAST1, TPH1 | ALDH1A1 1838/4885MEN1 1337/4885TP53 1977/4885 |
| US-20240239768-A1 | METHOD FOR PREPARING XANTHINE OXIDASE INHIBITOR | XDH, AOX1, PNPO | ALDH1A1 118/4885MEN1 3537/4885TP53 4883/4885 |
| US-20120184582-A1 | NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | XDH, PNPO, AOX1 | ALDH1A1 459/4885MEN1 4320/4885TP53 4873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.